our website WWW.PSI-CRO.COM or reach us at CONTACT@PSI-CRO.COM

For more information about PSI, please visit

Conducting trials in Hematology and Oncohematology are two of PSI’s core therapeutic

strengths. In recent years, PSI has run numerous studies in hematology, encompassing

blood dyscrasias from the more mundane to the rarest forms of hemophilia. Not to be

overlooked, we have tackled the study of the most difficult liquid tumor types as well. It is

remarkable that over 90% of PSI’s hematology/oncohematology studies completed

patient recruitment either on- time or ahead of schedule. The sites managed by PSI have

consistently shown stellar performance.

þMore than 50% of PSI’s operational staff has hematology/oncohematology experience,

thereby providing expertise to our sponsors in all aspects of planning, leveraging

investigator relationships, reviewing protocol complexities and executing all aspects of

clinical trials that will end on-time and on-budget. With a low staff turnover rate of <6%,

PSI continues to accumulate knowledge in a multitude of blood dyscrasias and liquid

tumors where numerous challenges abound. These are some of the most difficult studies

to conduct and PSI’s in-house familiarity with the nuances will benefit your team.

þWe have operational teams consisting of members of Senior Project Management, Project

Management, CRAs and Medical Affairs who focus on hematology and liquid tumors.

þPSI has conducted studies in different hemophilia populations: Hemophilia A and B,

previously treated and previously untreated, with and without inhibitors, adult and

pediatric, on prophylactic and on-demand treatment, undergoing minor and major

surgical procedures. We have worked with plasma-derived and recombinant FVIII and

FIX concentrates, as well as bypassing agents.

þPSI has worked with 150+ hemophilia treatment centers, globally, including KOLs from

Europe & North America. We have a database of 400+ known, potential hemophilia sites,

which have taken part in the feasibility process for each program we

have undertaken.

þPSI has conducted studies in oncohematology

malignancies including Multiple Myeloma, NHL, CLL, AML,

and Hodgkin’s Lymphoma at sites across Western,

Central and Eastern Europe, Latin America, Australia and

the US.

The PSI team exceeded

expectations, and execution of the protocol was exemplary. I’m proud of our

joint team and am grateful to have worked together.

Clinical Project Manager, USA

HEMATOLOGY & ONCOHEMATOLOGY

PSI has the following Phase I-IV experience in hematological indications:

Hematology Indications Oncohematology Indications

Acute Anemia Acute Myeloid Leukemia

Atypical Hemolytic Uremic Syndrome Anaplastic Large Cell Lymphoma

Idiopathic Thrombocytopenic Purpura Chemo Induced Neutropenia

Polycythemia Vera Chronic Lymphocytic Leukemia

Hemophilia A (includes Pediatric) Chronic Myeloid Leukemia

Hemophilia B (includes Pediatric) Follicular Non-Hodgkin's Lymphoma

Thrombocytopenia Hodgkin’s Lymphoma

Thrombotic Thrombocytopenic Purpura (TTP) Multiple Myeloma

Paroxysmal Nocturnal Hemoglobinuria (PNH) Non-Hodgkin’s Lymphoma

Von Willebrand Disease Relapsed Multiple Myeloma

Secondary Acute Myeloid Leukemia

Baarerstrasse 113a, 6300 Zug, Switzerland • Tel: +41 41 228 10 00

Global Office Locations

North America: Ft. Washington, PA / Burlingame, CA / San Francisco, CA

Latin America: Buenos Aires, Argentina

Europe: Oxford, UK / Munich, Germany / Neusiedl am See, Austria

Minsk, Belarus / Sofia, Bulgaria / Prague, Czech Republic / Tallinn, Estonia

Budapest, Hungary / Milan, Italy / Warsaw, Poland / Bucharest, Romania

Belgrade, Serbia / Kiev, Ukraine / Russian Federation: St. Petersburg, Moscow, Novosibirsk

Operational Presence by Region

North America / Europe / Latin America

Asia-Pacific / South Africa

PSI CRO AGCorporate Headquarters

WWW.PSI-CRO.COM

þPSI’s dedicated Feasibility Department, comprised of medical specialists, laboratory

experts, imaging specialists, logisticians and regulatory experts, has conducted feasibility

across a wide range of hematology and oncohematology indications. When we apply this

process to your trial and combine it with our knowledge of the smallest details and the

largest challenges of such intricate protocols, we are able to provide recommendations

for the best choice of sites, geography and realistic timelines for your study.